Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 1/20 | 0.45 |
| ▸ | MYC | P01106 | 1/20 | 0.44 |
| ▸ | WDR5 | P61964 | 1/20 | 0.44 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.43 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.43 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.41 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.41 |
| ▸ | TRPV3 | Q8NET8 | 2/20 | 0.40 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.40 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.40 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.40 |
| ▸ | AR | P10275 | 1/20 | 0.38 |
| ▸ | BDKRB1 | P46663 | 2/20 | 0.38 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.38 |
| ▸ | GSK3A | P49840 | 1/20 | 0.37 |
| ▸ | GSK3B | P49841 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | BRS3 | P32247 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10057911 | 1.00 | MME (0.45) | MMEMYCWDR5FFAR1AKR1B1 | |
| SCHEMBL8065614 | 0.82 | MYC (0.45) | MMEMYCWDR5FFAR1AKR1B1 | |
| SCHEMBL2432 | 0.82 | MYC (0.45) | MMEMYCWDR5FFAR1AKR1B1 | |
| SCHEMBL2174 | 0.82 | MYC (0.45) | MMEMYCWDR5FFAR1AKR1B1 | |
| SCHEMBL2132 | 0.81 | MYC (0.47) | MMEMYCWDR5FFAR1AKR1B1 | |
| SCHEMBL2870 | 0.81 | MYC (0.47) | MMEMYCWDR5FFAR1AKR1B1 | |
| Hydrochloric Acid SCHEMBL15663201 | 0.81 | MYC (0.45) | MMEMYCWDR5FFAR1AKR1B1 | |
| Hydrochloric Acid SCHEMBL3526296 | 0.81 | MYC (0.45) | MMEMYCWDR5FFAR1AKR1B1 | |
| SCHEMBL6509544 | 0.79 | MME (0.48) | MMEMYCWDR5FFAR1AKR1B1 | |
| SCHEMBL1696979 | 0.79 | MME (0.48) | MMEMYCWDR5FFAR1AKR1B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8258312-B2 | Process for preparing pure valsartan | MYLAN LABORATORIES LTD (IN) | 2012-09-04 | — | — | US | disclosed |
| US-7923567-B2 | Process for preparing valsartan | ALEMBIC LIMITED (IN) | 2011-04-12 | — | — | US | disclosed |
| US-20100249430-A1 | PROCESS FOR PREPARING VALSARTAN | ALEMBIC LIMITED (IN) | 2010-09-30 | — | — | US | disclosed |
| US-20100197932-A1 | PROCESS FOR PREPARING PURE VALSARTAN | MATRIX LABORATORIES LTD (IN) | 2010-08-05 | — | — | US | disclosed |
| US-7741507-B2 | Process for preparing Valsartan | ALEMBIC LIMITED (IN) | 2010-06-22 | — | — | US | disclosed |
| US-7659406-B2 | Process for preparing valsartan | DR. REDDY'S LABORATORIES LIMITED (IN) | 2010-02-09 | — | — | US | disclosed |
| EP-1926705-B1 | PROCESS FOR PREPARING VALSARTAN | ALEMBIC LTD (IN) | 2009-09-02 | — | — | EP | disclosed |
| WO-2008007391-A2 | AN IMPROVED PROCESS FOR THE PREPARATION OF VALSARTAN | SATYANARAYANA REDDY MANNE (IN) | 2008-01-17 | — | — | WO | disclosed |
| WO-2007057919-A2 | AN IMPROVED PROCESS FOR PREPARATION OF (S)-N-(1-CARBOXY-2-METHYL-PROP-1-YL)-N-PENTANOYL-N-[2'-(1H-TETRAZOL-5-YL)BIPHENYL-4-YLMETHYL]-AMINE | ALEMBIC LIMITED (IN) | 2007-05-24 | — | — | WO | disclosed |
| WO-2007032019-A2 | PROCESS FOR PREPARING VALSARTAN | ALEMBIC LIMITED (IN) | 2007-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100197932-A1 | PROCESS FOR PREPARING PURE VALSARTAN | AGT, ACE, REN | MME 10/4885MYC 4701/4885WDR5 2718/4885 |
| US-20100249430-A1 | PROCESS FOR PREPARING VALSARTAN | REN, AGTR1, AGT | MME 61/4885MYC 4415/4885WDR5 2543/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.